Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy
The number of blind and low vision persons in the US is projected to increase to 5.68 million by 2020. The eye diseases causing loss of vision are life-long, chronic, and often need protracted presence of therapeutics at the disease site to keep the disease in remission. In addition, multiple pathol...
Main Authors: | David Warther, Ying Xiao, Fangting Li, Yuqin Wang, Kristyn Huffman, William R. Freeman, Michael Sailor, Lingyun Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2018.1486474 |
Similar Items
-
New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies
by: Sang Woong Moon, et al.
Published: (2018-01-01) -
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
by: Frederico Luiz Dulley, et al. -
Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature
by: Claudio Iovino, et al.
Published: (2020-07-01) -
In Vitro Dissolution Methods for Hydrophilic and Hydrophobic Porous Silicon Microparticles
by: Jarno Salonen, et al.
Published: (2011-06-01) -
Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®)
by: Daniel H. Lee, et al.
Published: (2020-09-01)